Document

6-K 1 a240718_6kxmorxvotingright.htm 6-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2024

COMMISSION FILE NUMBER 001-38455

MorphoSys AG

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

On July 18, 2024, MorphoSys AG (the “Company”) published a notification on receipt of a letter of intent from Novartis BidCo Germany AG (pursuant to Section 43 (1) WpHG).

Exhibits

99.1 Notification on receipt of a letter of intent from Novartis BidCo Germany AG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MORPHOSYS AG (Registrant)

Date: July 18, 2024

By: /s/ i.A. Kristina Grötsch

Name: Kristina Grötsch

Title: Manager Investor Relations

By: /s/ i.A. Isabelle Degbegni

Name: Isabelle Degbegni

Title: Director Investor Relations

SEC Form 6-K filed by MorphoSys AG